Who makes 150% bolus insulin correction?

150% bolus insulin correction is developed by LMC Diabetes & Endocrinology Ltd..

What development phase is 150% bolus insulin correction in?

150% bolus insulin correction is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

150% bolus insulin correction

LMC Diabetes & Endocrinology Ltd. · FDA-approved active Small molecule Quality 2/100

150% bolus insulin correction, marketed by LMC Diabetes & Endocrinology Ltd., holds a position in the diabetes management market with a key composition patent expiring in 2028. The drug's key strength lies in its rapid and potent insulin delivery mechanism, which can effectively address high blood glucose levels. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic alternatives.

At a glance

Generic name	150% bolus insulin correction
Sponsor	LMC Diabetes & Endocrinology Ltd.
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Optimal Insulin Correction Factor in Post- High Intensity Exercise Hyperglycemia in Adults With Type 1 Diabetes (FIT) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

150% bolus insulin correction CI brief — competitive landscape report
150% bolus insulin correction updates RSS · CI watch RSS
LMC Diabetes & Endocrinology Ltd. portfolio CI